Restoring Life’s Potential by Enabling the Nervous System to Repair Itself after Neurologic Trauma and Disease
Joined May 2019
- Tweets 627
- Following 227
- Followers 6,096
- Likes 116
214 Photos and videos
May 26
NervGen today announced positive independent, blinded biomechanical gait analyses demonstrating genuine neural recovery with NVG-291 in the Phase 1b/2a CONNECT SCI study.
Read the full news release: nervgen.com/nervgen-announce…
#SCI #SpinalCordInjury
4
24
1,202
May 18
NervGen today reported financial results for the first quarter ended March 31, 2026, and provided business updates.
Read the full news release: nervgen.com/nervgen-reports-…
#SCI #SpinalCordInjury
2
14
803
Apr 27
NervGen today announced the appointment of Keith Vendola, MD, MBA, as Chief Financial Officer to lead financial strategy and operations.
nervgen.com/nervgen-pharma-s…
#SCI #SpinalCordInjury
5
21
894
Apr 13
NervGen today announced that Adam Rogers, MD, President and Chief Executive Officer, and other members of the Company’s executive leadership team, are scheduled to participate in a fireside chat during the virtual H.C. Wainwright “HCW@Home” series and present at the 2026 Bloom Burton & Co. Healthcare Investor Conference.
nervgen.com/nervgen-pharma-t…
#SCI
5
22
709
NervGen today announced the completion of a successful End-of-Phase 2 (EOP2) meeting and alignment on RESTORE, the Company’s Phase 3 registrational study designed to evaluate NVG-291 for the treatment of chronic tetraplegia.
RESTORE initiation remains on-track for mid-2026, with study initiation activities underway.
Read the full news release: nervgen.com/nervgen-pharma-a…
#SCI #SpinalCordInjury
8
36
1,669
Mar 31
NervGen Pharma today reported its full year 2025 financial results and provided business updates.
Read the full news release: nervgen.com/nervgen-pharma-r…
#SCI #SpinalCordInjury
5
26
1,273
Mar 23
NervGen’s CEO, Dr. Adam Rogers, joined @biotechnation to share the story behind NVG-291, from Dr. Jerry Silver’s pioneering research and Harold Punnett’s founding vision to what NervGen’s CONNECT SCI clinical data now shows is possible for individuals living with chronic spinal cord injury.
biotechnation.com/episodes/r…
#SCI #SpinalCordInjury
9
28
1,094
Mar 12
NervGen Pharma today announced that the Company has elected to voluntarily delist its common shares from the TSX Venture Exchange, effective March 16, 2026.
The Company’s common shares will continue to trade on Nasdaq under the symbol “NGEN,” and no action is required by shareholders. All shareholders, including Canadian shareholders, will continue to maintain full trading access on Nasdaq.
Read the full news release: nervgen.com/nervgen-pharma-a…
#SCI #SpinalCordInjury
1
15
766
NervGen today appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as Senior Vice President (SVP), Patient Advocacy and Clinical Affairs.
nervgen.com/nervgen-pharma-a…
#SCI
3
18
940
Feb 18
NervGen today announced that Adam Rogers, MD, President and Chief Executive Officer, and other members of the Company’s executive leadership team, are scheduled to participate in multiple upcoming investor conferences.
nervgen.com/nervgen-pharma-t…
#SCI
6
24
928
Feb 11
NervGen today announced it will present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium, which is being held February 15-17, 2026, in Washington, DC.
nervgen.com/nervgen-pharma-t…
#SCI #SpinalCordInjury #CNS #NeuroRepair #Biotech
7
24
713
NervGen today announced it has appointed Adam Rogers, MD, as President and CEO. Dr. Rogers will continue leading the Company’s growth and execution of its mission to transform the lives of individuals living with spinal cord injury.
nervgen.com/nervgen-pharma-a…
#SCI
7
23
1,064
Jan 23
🎉A proud moment for our team!
NervGen celebrated its @Nasdaq listing by ringing the closing bell yesterday in Times Square. A significant milestone and the beginning of an exciting year ahead.
View the full ceremony: nasdaq.com/events/nervgen-ph…
#SCI #SpinalCordInjury
13
51
1,768
Jan 20
NervGen Pharma today announced that it will ring the closing bell at the Nasdaq Stock Market on Thursday, January 22, 2026, in New York City.
nervgen.com/nervgen-pharma-t…
#SCI #SpinalCordInjury
1
8
29
1,274
NervGen Pharma today announced that the company's common shares have been approved for listing on Nasdaq and will begin trading today under the symbol “NGEN.”
nervgen.com/nervgen-pharma-b…
#SCI #SpinalCordInjury
12
31
2,184
19 Dec 2025
Thank you, @Forbes and @TheAlexKnapp, for featuring NVG-291 in this week’s edition of The Prototype!
This Company’s Drug May Help Regenerate Injured Spinal Cords forbes.com/sites/the-prototy…
5
34
1,834
18 Dec 2025
NervGen CEO Adam Rogers spoke with @BioSpace about the unprecedented CONNECT SCI data showing NVG-291 improved function, independence & quality of life in chronic #SCI with reported durability up to 1 year after the 16-week study period.
biospace.com/drug-developmen…
#SpinalCordInjury
12
39
2,327
24 Nov 2025
NervGen reports its third quarter 2025 financial results and provides business updates.
Read the full release here: nervgen.com/nervgen-pharma-r…
#SCI #SpinalCordInjury #News
6
30
2,483
24 Nov 2025
NervGen today announced expanded CONNECT SCI Study data demonstrating unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic SCI.
nervgen.com/nervgen-pharma-a…
#SCI #SpinalCordInjury #News
20
55
3,898